258 related articles for article (PubMed ID: 26878872)
41. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
Ye ZY; Cao YB; Lin TY; Lin HL
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
[TBL] [Abstract][Full Text] [Related]
42. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
44. Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature.
Bhagavathi S; Micale MA; Les K; Wilson JD; Wiggins ML; Fu K
Am J Surg Pathol; 2009 Oct; 33(10):1463-9. PubMed ID: 19675454
[TBL] [Abstract][Full Text] [Related]
45. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
[TBL] [Abstract][Full Text] [Related]
46. Focal adhesion protein expression in human diffuse large B-cell lymphoma.
Bosch R; Dieguez-Gonzalez R; Moreno MJ; Gallardo A; Novelli S; Espinosa I; Céspedes MV; Pavón MÁ; Briones J; Grañena A; Sierra J; Mangues R; Casanova I
Histopathology; 2014 Jul; 65(1):119-31. PubMed ID: 24467224
[TBL] [Abstract][Full Text] [Related]
47. TNF-α expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified.
Nakayama S; Yokote T; Hirata Y; Akioka T; Miyoshi T; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Tsuji M; Hanafusa T
Am J Surg Pathol; 2014 Feb; 38(2):228-34. PubMed ID: 24145654
[TBL] [Abstract][Full Text] [Related]
48. p63 and p53 expression in extranodal NK/T cell lymphoma, nasal type.
Ye Z; Cao Q; Niu G; Liang Y; Liu Y; Jiang L; Yu X; Han A
J Clin Pathol; 2013 Aug; 66(8):676-80. PubMed ID: 23626008
[TBL] [Abstract][Full Text] [Related]
49. TNF-α receptor 1 expression predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified.
Nakayama S; Yokote T; Tsuji M; Akioka T; Miyoshi T; Hirata Y; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Hanafusa T
Am J Surg Pathol; 2014 Aug; 38(8):1138-46. PubMed ID: 24805855
[TBL] [Abstract][Full Text] [Related]
50. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
51. Clinico-pathological characteristics of p63 expression in B-cell lymphoma.
Fukushima N; Satoh T; Sueoka N; Sato A; Ide M; Hisatomi T; Kuwahara N; Tomimasu R; Tsuneyoshi N; Funai N; Sano M; Tokunaga O; Sueoka E
Cancer Sci; 2006 Oct; 97(10):1050-5. PubMed ID: 16918993
[TBL] [Abstract][Full Text] [Related]
52. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
[TBL] [Abstract][Full Text] [Related]
53. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.
Vasmatzis G; Johnson SH; Knudson RA; Ketterling RP; Braggio E; Fonseca R; Viswanatha DS; Law ME; Kip NS; Ozsan N; Grebe SK; Frederick LA; Eckloff BW; Thompson EA; Kadin ME; Milosevic D; Porcher JC; Asmann YW; Smith DI; Kovtun IV; Ansell SM; Dogan A; Feldman AL
Blood; 2012 Sep; 120(11):2280-9. PubMed ID: 22855598
[TBL] [Abstract][Full Text] [Related]
54. [Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma].
Yao XX; Wang JF; Wang YH; Gao N
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):366-70. PubMed ID: 22932402
[TBL] [Abstract][Full Text] [Related]
55. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
[TBL] [Abstract][Full Text] [Related]
56. Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma.
Saez AI; García-Cosío M; Sáez AJ; Hernández JM; Sánchez-Verde L; Alvarez D; de la Cueva P; Arranz R; Conde E; Grande C; Rodríguez J; Caballero D; Piris MA
Leuk Lymphoma; 2009 Apr; 50(4):571-81. PubMed ID: 19373655
[TBL] [Abstract][Full Text] [Related]
57. The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
Pătraşcu AM; Rotaru I; Olar L; Pătraşcu Ş; Ghiluşi MC; NeamŢu SD; Nacea JG; Gluhovschi A
Rom J Morphol Embryol; 2017; 58(3):837-843. PubMed ID: 29250662
[TBL] [Abstract][Full Text] [Related]
58. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
[TBL] [Abstract][Full Text] [Related]
59. Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients.
Wang J; Zhou M; Zhang QG; Xu J; Lin T; Zhou RF; Li J; Yang YG; Chen B; Ouyang J
Oncotarget; 2017 Feb; 8(6):9708-9716. PubMed ID: 28039454
[TBL] [Abstract][Full Text] [Related]
60. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]